Mobile Site ›

The Classic Myeloproliferative Neoplasms

Optimizing Laboratory Testing for Hematologic Disorders Series

JAK2 Exon 12 Sequencing

Slide 19

October 2011

When we looked back at 92 cases at Mayo Clinic that had JAK2 exon 12 sequencing studies done, we found that only 25% were appropriately requested–those that had a negative V617F and had a PV-like CBC with decreased serum erythropoietin. 75% of these 92 requests appeared to be inappropriately ordered since they had no JAK2 V617F testing, or had positive JAK2 V617F results, or had a bone marrow with no morphologic features of a myeloproliferative disorder, or a peripheral blood that had no PV-like CBC with normal serum erythropoietin values.

JAK2 Exon 12 Sequencing


Jump to section: